
QTTB
Healthcare · Biotechnology · $260.6M market cap
$8.71-0.11 (-1.2%)Nov 13, 4:00 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +6.9% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 4 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 4, 2026 | Before the open | -0.36 | -0.26 | +27.8% |
| Aug 5, 2026 | Before the open | -0.53 | -0.44 | +17.0% |
| May 5, 2026 | Before the open | -0.68 | -0.54 | +20.6% |
| Mar 10, 2026 | Time not confirmed | -0.86 | 4.58 | +632.6% |
| Nov 13, 2025 | Before the open | -1.19 | -0.60 | +49.6% |
| Aug 6, 2025 | Before the open | -0.98 | -0.78 | +20.4% |
| May 8, 2025 | Before the open | -1.23 | -0.90 | +26.8% |
| Mar 11, 2025 | Before the open | -1.53 | -1.16 | +24.2% |
| Nov 7, 2024 | Before the open | -1.45 | -1.46 | -0.7% |
| Aug 8, 2024 | Before the open | -1.04 | -1.42 | -36.5% |
| May 9, 2024 | Before the open | -1.41 | 1.03 | +173.0% |
| Mar 13, 2024 | Before the open | -0.30 | -0.28 | +6.7% |
| Nov 14, 2023 | Time not confirmed | -0.43 | -0.57 |
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to…
| -32.6% |
| Aug 14, 2023 | Time not confirmed | -0.50 | -0.61 | -22.0% |
| May 11, 2023 | Time not confirmed | -0.52 | -0.50 | +3.8% |
| Mar 9, 2023 | Time not confirmed | -0.49 | -10.80 | -2094.2% |
| Nov 10, 2022 | Time not confirmed | -0.46 | -10.62 | -2226.9% |
| Aug 15, 2022 | Time not confirmed | -0.54 | -9.18 | -1607.6% |
| May 16, 2022 | Time not confirmed | -0.49 | 28.62 | +5910.0% |
| Mar 23, 2022 | Time not confirmed | -0.57 | -10.62 | -1748.9% |
| Nov 15, 2021 | Time not confirmed | -0.59 | -9.72 | -1555.9% |
| Aug 12, 2021 | Time not confirmed | -0.57 | -9.72 | -1590.4% |
| May 6, 2021 | Time not confirmed | -0.61 | -0.36 | +41.3% |
| Mar 11, 2021 | Time not confirmed | -0.66 | -11.16 | -1594.0% |
| Nov 9, 2020 | Time not confirmed | -0.81 | -11.16 | -1279.8% |
| Aug 10, 2020 | Time not confirmed | -0.74 | -14.04 | -1797.3% |
| May 7, 2020 | Time not confirmed | -0.69 | -14.04 | -1934.8% |
| Mar 12, 2020 | Time not confirmed | -0.68 | -9.90 | -1355.9% |
| Nov 12, 2019 | Time not confirmed | -0.60 | -12.06 | -1910.0% |
| Aug 8, 2019 | Time not confirmed | -0.55 | -10.98 | -1896.4% |
| May 13, 2019 | Time not confirmed | -0.54 | -11.52 | -2033.3% |
| Mar 12, 2019 | Time not confirmed | -0.44 | -9.18 | -1986.4% |
| Nov 13, 2018 | Time not confirmed | -0.37 | -7.20 | -1845.9% |
| Aug 13, 2018 | Time not confirmed | -0.33 | -0.16 | +51.5% |
| May 14, 2018 | Time not confirmed | -3.78 | -0.15 | +96.0% |
| Feb 28, 2018 | Time not confirmed | — | -0.32 | — |